BR0207283A - Anticorpos anti-egfr modificados com imunogenicidade reduzida - Google Patents

Anticorpos anti-egfr modificados com imunogenicidade reduzida

Info

Publication number
BR0207283A
BR0207283A BR0207283-1A BR0207283A BR0207283A BR 0207283 A BR0207283 A BR 0207283A BR 0207283 A BR0207283 A BR 0207283A BR 0207283 A BR0207283 A BR 0207283A
Authority
BR
Brazil
Prior art keywords
antibodies
reduced immunogenicity
modified anti
egfr antibodies
egfr
Prior art date
Application number
BR0207283-1A
Other languages
English (en)
Inventor
Francis J Carr
Graham Carter
Tim Jones
Stephen Williams
Anita Hamilton
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0207283A publication Critical patent/BR0207283A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"ANTICORPOS ANTI-EGFR MODIFICADOS COM IMUNOGENICIDADE REDUZIDA". A presente invenção refere-se a anticorpos que são direcionados para o receptor de EGF (HER1) para serem administrados especialmente a seres humanos e em particular para uso terapêutico em tumores. Os anticorpos são modificados através de modificação que resulta em uma propensão reduzida do anticorpo de ativar uma resposta imunológica após a administração ao indivíduo humano. A invenção refere-se em particular à modificação do anticorpo anti-EGFR 425 em suas diferentes formas e fragmentos dos mesmos para resultar nas variações do MAb 425 que são substancialmente não imunogênicas ou menos imunogênicas que qualquer correspondente não modificado quando utilizadas in vivo.
BR0207283-1A 2001-02-19 2002-02-18 Anticorpos anti-egfr modificados com imunogenicidade reduzida BR0207283A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01103954 2001-02-19
PCT/EP2002/001687 WO2002066058A1 (en) 2001-02-19 2002-02-18 Modified anti-egfr antibodies with reduced immunogenicity

Publications (1)

Publication Number Publication Date
BR0207283A true BR0207283A (pt) 2004-08-17

Family

ID=8176531

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207283-1A BR0207283A (pt) 2001-02-19 2002-02-18 Anticorpos anti-egfr modificados com imunogenicidade reduzida

Country Status (14)

Country Link
US (1) US7132511B2 (pt)
EP (1) EP1361893B1 (pt)
JP (1) JP2004519233A (pt)
KR (1) KR20030074839A (pt)
CN (1) CN100488563C (pt)
BR (1) BR0207283A (pt)
CA (1) CA2438513C (pt)
ES (1) ES2398099T3 (pt)
HU (1) HUP0303173A2 (pt)
MX (1) MXPA03007319A (pt)
PT (1) PT1361893E (pt)
RU (1) RU2297245C2 (pt)
WO (1) WO2002066058A1 (pt)
ZA (1) ZA200307329B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040074587A (ko) * 2001-02-19 2004-08-25 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 인공 단백질
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
WO2002092771A2 (en) 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
CA2472937C (en) 2002-01-11 2014-06-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US20040109855A1 (en) * 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
RU2349340C2 (ru) * 2002-10-10 2009-03-20 Мерк Патент Гмбх Биспецифические антитела к erb-b и их применение для лечения опухолей
EP1656391B1 (en) 2003-08-13 2010-10-13 Pfizer Products Inc. Modified human igf-1r antibodies
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
JP2009532358A (ja) * 2006-03-31 2009-09-10 マサチューセッツ・インスティテュート・オブ・テクノロジー 突然変異型ｅｇｆ受容体を発現する腫瘍の治療
WO2008077171A1 (en) * 2006-12-22 2008-07-03 Novelix Therapeutics Gmbh Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
AU2007339773B2 (en) * 2006-12-27 2011-03-10 The Johns Hopkins University Compositions and methods for stimulating an immune response
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
ES2582386T3 (es) * 2007-03-01 2016-09-12 Symphogen A/S Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico
MX2009009782A (es) 2007-03-15 2010-09-10 Ludwig Inst Cancer Res Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
US8252897B2 (en) * 2007-06-21 2012-08-28 Angelica Therapeutics, Inc. Modified toxins
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
KR101956059B1 (ko) 2008-06-25 2019-03-08 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
RU2567006C2 (ru) * 2008-06-25 2015-10-27 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Гуманизация антител кролика с использованием универсального каркаса антитела
RU2652907C2 (ru) * 2008-06-25 2018-05-03 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Гуманизация антител кролика с использованием универсального каркаса антитела
KR101706255B1 (ko) * 2008-08-29 2017-02-14 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
BRPI1006141B8 (pt) 2009-01-12 2021-05-25 Cytomx Therapeutics Llc composições de anticorpo modificado, métodos para preparar e usar as mesmas
JP5861223B2 (ja) 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
US9011853B2 (en) 2009-08-31 2015-04-21 Amplimmune, Inc. B7-H4 fusion proteins and methods of use thereof
MX352871B (es) * 2009-12-23 2017-12-13 Esbatech Alcon Biomed Res Unit Método para disminuir inmunogenicidad.
NZ609619A (en) 2010-10-29 2015-05-29 Immunogen Inc Novel egfr-binding molecules and immunoconjugates thereof
WO2012058592A2 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Non-antagonistic egfr-binding molecules and immunoconjugates thereof
BR112014002219A2 (pt) 2011-07-05 2018-08-07 Bioasis Technologies Inc conjugados anticorpo p97 e métodos de sua utilização
CA2842492A1 (en) 2011-08-05 2013-02-14 Bioasis Technologies, Inc. P97 fragments with transfer activity
JP2014533954A (ja) 2011-11-21 2014-12-18 イミュノジェン， インコーポレイテッド Ｅｇｆｒ抗体細胞傷害性薬物複合体による、ｅｇｆｒ療法に耐性である腫瘍の治療方法
JP6433424B2 (ja) 2012-07-31 2018-12-05 バイオアシス テクノロジーズ インコーポレイテッド 脱リン酸化されたリソソーム蓄積症タンパク質およびその使用方法
BR112015022416A2 (pt) 2013-03-13 2017-10-24 Bioasis Technologies Inc fragmentos de p97 e seus usos
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
WO2015031673A2 (en) 2013-08-28 2015-03-05 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
KR20160055253A (ko) 2013-09-12 2016-05-17 할로자임, 아이엔씨 변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법
ES2764973T3 (es) 2014-02-03 2020-06-05 Bioasis Technologies Inc Proteínas de fusión de P97
US10392605B2 (en) 2014-02-19 2019-08-27 Bioasis Technologies Inc. P97-IDS fusion proteins
US10058619B2 (en) 2014-05-01 2018-08-28 Bioasis Technologies, Inc. P97-polynucleotide conjugates
WO2016062851A1 (en) 2014-10-23 2016-04-28 Innate Pharma Treatment of cancers using anti-nkg2a agents
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
US20200339639A1 (en) * 2018-01-11 2020-10-29 Uti Limited Partnership Treatment of fragile x syndrome
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CN113330033A (zh) 2018-12-26 2021-08-31 先天制药公司 白细胞免疫球蛋白样受体2中和性抗体
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
WO2023007023A1 (en) 2021-07-30 2023-02-02 Affimed Gmbh Duplexbodies
AU2022382368A1 (en) 2021-11-03 2024-05-02 Affimed Gmbh Bispecific cd16a binders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
CZ282603B6 (cs) * 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
AU6267896A (en) * 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
DE69833755T2 (de) * 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
EP1051432B1 (en) * 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins

Also Published As

Publication number Publication date
CN1492767A (zh) 2004-04-28
US7132511B2 (en) 2006-11-07
CA2438513C (en) 2013-08-13
EP1361893B1 (en) 2012-10-24
WO2002066058A1 (en) 2002-08-29
ES2398099T3 (es) 2013-03-13
HUP0303173A2 (hu) 2003-12-29
JP2004519233A (ja) 2004-07-02
RU2003127410A (ru) 2005-03-20
KR20030074839A (ko) 2003-09-19
MXPA03007319A (es) 2003-12-04
ZA200307329B (en) 2005-02-23
PT1361893E (pt) 2013-01-24
CA2438513A1 (en) 2002-08-29
EP1361893A1 (en) 2003-11-19
RU2297245C2 (ru) 2007-04-20
PL362413A1 (en) 2004-11-02
CN100488563C (zh) 2009-05-20
US20040096442A1 (en) 2004-05-20

Similar Documents

Publication Publication Date Title
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
BR0007840A (pt) Proteìnas de fusão her-2/neu
BR0208041A (pt) Interferon beta modificado com imunogenicidade reduzida
BR0207016A (pt) Fator neurotrófico derivado de cérebro humano modificado (bdnf) com imunogenicidade reduzida
BR0114786A (pt) Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
BR0209177A (pt) Anticorpo especìfico a tumor recombinante e uso do mesmo
PL377337A1 (pl) Humanizowane przeciwciało (H14.18) z mysiego przeciwciała 14.18 wiążące GD2 oraz jego połączenie z IL-2
PT1336621E (pt) Respostas imunitarias contra antigenios dos vph, suscitadas por composicoes que incorporam um antigenio de vph e uma proteina do stress ou um vector de expressao com aptidao para a expressao destas proteinas
BRPI0010612B8 (pt) vacinas
WO2003030934A3 (en) Cpg formulations and related methods
BR9913446A (pt) Produtos de aglicona e métodos de uso
PT910407E (pt) Metodo e composicao para modificar a conformacao de antigenios multi-epitopicos de modo a iniciar uma resposta imunitaria
ATE373017T1 (de) Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen
HK1093314A1 (en) Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
WO2000025722A3 (en) ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS
WO2002085311A3 (en) Hcg formulation
BR0010682A (pt) Novas composições
BR0207018A (pt) Leptina modificada com imunogenicidade reduzida
BR0308860A (pt) Fator viii modificado
BR0207014A (pt) Antagonista de receptor de interleucina-1 modificada (il-1ra) com imunogenicidade reduzida.
BR0207704A (pt) Alfa interferon modificado com imunogenicidade reduzida
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
BR0207015A (pt) Eritropoientina modificada (epo) com imunogenicidade reduzida
BR0009781A (pt) Anticorpos antiidiotìpicos contra anticorpos que inibem a ligação de imunoglobulina e ao seu receptor de alta afinidade

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.